Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Income Before Tax

Profit after all operating and non-operating items but before income tax.

Standard BioTools Inc.NASDAQ: LAB

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$14.62M, compared with -$23.49M a year earlier. Trailing-twelve-month income before tax was -$87.83M.

Context

  • Income before tax amounted to 113.3% of revenue in FY2025, up 34.0 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$14.62M or moves back toward the trailing-twelve-month quarterly average of -$21.96M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.62M+33.7% QoQ
Last fiscal yearDec 2025
-$96.7M+30.1% YoY
LTMMar 2026
-$87.83M+19.8% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.8%——
1 year+30.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(96.7M) USD
Year-over-year change
+30.1%

Income Before Tax vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +19.8% is the 4th highest of 11, against a peer median of -4.7%.
  • Income before tax amounts to 101.8% of revenue for LAB, versus a peer median of 16.3%.
LAB Competitors
Income Before Tax for LAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BVSBioventus Inc.LTM Mar 2026$33.64M USD+167.9%—5.8%
CTKBCytek Biosciences, Inc.LTM Mar 2026-$35.95M USD-350.9%—17.6%
KIDSOrthoPediatrics Corp.LTM Mar 2026-$39.58M USD+5.9%—16.3%
CBLLCeriBell, Inc.LTM Mar 2026-$60.37M USD-35.7%—63.5%
TMCITreace Medical Concepts, Inc.LTM Mar 2026-$61.04M USD-15.2%—29.4%
AVNSAvanos Medical, Inc.LTM Mar 2026-$68.3M USD+82.7%—9.5%
VREXVarex Imaging CorporationLTM Apr 2026-$75.1M USD-552.4%—8.8%
LABStandard BioTools Inc.LTM Mar 2026-$87.83M USD+19.8%—101.8%
ADCTADC Therapeutics S.A.LTM Mar 2026-$136.14M USD+9.0%—171.9%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$221.04M USD-23.7%——
SYSo-Young International Inc.LTM Mar 2026-CN¥260.42M CNY+56.6%—15.8%
Peer median (excluding LAB) —-4.7%—16.3%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.58M97.95M106.34M174.43M85.33M
Cost of Revenue61.21M60.9M55.89M90.17M42.79M
Gross Profit69.37M37.05M50.45M84.26M42.54M
Gross Margin53.1%37.8%47.4%48.3%49.9%
Research & Development37.94M37.38M25.95M62.41M25.99M
Selling, General & Admin98.89M102.29M87.54M156.61M109.86M
Operating Expenses136.83M153.26M127.05M259.5M135.85M
Depreciation & Amortization15.57M15.03M15.18M16.86M6.98M
EBITDA(44.27M)(173.57M)(54.46M)(118.14M)(89.69M)
EBITDA Margin-33.9%-177.2%-51.2%-67.7%-105.1%
Operating Income(67.46M)(116.21M)(76.6M)(175.24M)(93.31M)
Operating Margin-51.7%-118.6%-72.0%-100.5%-109.3%
Interest Income02.23M5.57M20.2M9.18M
Interest Expense3.82M4.33M4.57M3.32M26K
Other Income / Expenses3.8M(76.72M)2.4M36.92M(3.4M)
Income Before Tax(63.66M)(192.93M)(74.2M)(138.31M)(96.7M)
Pre-Tax Margin-48.8%-197.0%-69.8%-79.3%-113.3%
Income Tax Expense(4.42M)(2.83M)452K573K(37.88M)
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Net Margin-45.4%-194.1%-70.2%-79.6%-87.8%
EPS (Basic)(0.78)(2.43)(0.94)(0.52)(0.20)
EPS (Diluted)(0.78)(2.43)(0.94)(0.52)(0.20)
Weighted Avg Shares75.79M78.31M79.16M352.67M381.62M
Weighted Avg Shares (Diluted)75.79M78.31M79.16M352.67M381.62M

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.